BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15087407)

  • 41. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
    Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
    J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
    Terasaki Y; Shichijo S; Niu Y; Komatsu N; Noguchi M; Todo S; Itoh K
    Cancer Immunol Immunother; 2009 Nov; 58(11):1877-85. PubMed ID: 19330328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
    Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
    Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.
    Jia ZC; Tian Y; Huang ZM; Wang JX; Fu XL; Ni B; Wu YZ
    Cancer Biol Ther; 2011 Feb; 11(4):395-400. PubMed ID: 21124073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
    Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
    Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
    Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
    Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K
    Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
    Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
    Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4.
    Jia ZC; Ni B; Huang ZM; Tian Y; Tang J; Wang JX; Fu XL; Wu YZ
    Clin Dev Immunol; 2010; 2010():567594. PubMed ID: 21350607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
    Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
    Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
    Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
    Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL.
    Koga M; Shichijo S; Yamada A; Ashihara J; Sawamizu H; Kusukawa J; Itoh K
    Tissue Antigens; 2003 Feb; 61(2):136-45. PubMed ID: 12694581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
    Matsueda S; Yamada A; Takao Y; Tamura M; Komatsu N; Yutani S; Ide T; Sata M; Itoh K
    Cancer Immunol Immunother; 2007 Sep; 56(9):1359-66. PubMed ID: 17265020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope.
    Kan-Mitchell J; Bisikirska B; Wong-Staal F; Schaubert KL; Bajcz M; Bereta M
    J Immunol; 2004 May; 172(9):5249-61. PubMed ID: 15100263
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
    Arai J; Yasukawa M; Ohminami H; Kakimoto M; Hasegawa A; Fujita S
    Blood; 2001 May; 97(9):2903-7. PubMed ID: 11313288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
    Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.